Potentiation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer.
The ability of lonidamine, an energolytic derivative of indazole-carboxylic acid, to modulate the cytotoxic activity of cisplatin was investigated on primary cultures obtained from 11 human ovarian carcinomas. A 72-h postincubation with lonidamine potentiated the activity of a 1-h cisplatin treatment. Statistical analysis of the dose-effect plots indicated that the interaction between the two drugs was synergistic in 4 tumors and additive in the remaining 7 tumors. The occurrence of the synergistic effect was independent of some biological characteristics of the tumor cell population, such as cell kinetics (as assessed by 3H-thymidine labeling index), DNA content and the expression of the putative factor of cisplatin resistance, glutathione-S-transferase pi.
Orlandi
L
L
Divisione di oncologia Sperimentale C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Zaffaroni
N
N
Gornati
D
D
Veneroni
S
S
Silvestrini
R
R
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007191:Indazoles / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D007191:Indazoles; D002945:Cisplatin; C016371:lonidamine